Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Forge Biologics
Forge Biologics Announces Planned CEO Succession
September 10, 2024
From
Forge Biologics
Via
Business Wire
Muscular Dystrophy Association and Forge Biologics Announce AAV Development and Manufacturing Partnership
September 09, 2024
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 30, 2024
From
Forge Biologics
Via
Business Wire
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
March 19, 2024
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote
January 29, 2024
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production
December 12, 2023
From
Forge Biologics
Via
Business Wire
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
November 13, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs
October 11, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics to Participate in Multiple September Investor Conferences
September 05, 2023
From
Forge Biologics
Via
Business Wire
New Hope Research Foundation and Forge Biologics Announce cGMP Manufacturing Partnership to Accelerate Gene Therapy for Patients with Tay-Sachs Disease
June 28, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Joins Bespoke Gene Therapy Consortium (BGTC) as Partner to Accelerate the Development and Manufacturing of AAV Gene Therapies for Patients with Rare Diseases
May 23, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 11, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration
May 03, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs
April 24, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium
February 23, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development
January 25, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease
January 17, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership
January 10, 2023
From
Forge Biologics
Via
Business Wire
Forge Biologics, a Leading Manufacturer of Genetic Medicines, to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Forge Biologics
Via
Business Wire
Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership
November 29, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
October 11, 2022
From
Forge Biologics
Via
Business Wire
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
October 10, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics to Present and Participate at Upcoming Investor Conferences
September 29, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients
September 27, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
September 12, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics to Present at Morgan Stanley’s 20th Annual Global Healthcare Conference
September 07, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium
August 30, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics to Present at Annual Jefferies Global Healthcare Conference
May 31, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders
May 17, 2022
From
Forge Biologics
Via
Business Wire
Forge Biologics Announces 7 Presentations at the Upcoming Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 02, 2022
From
Forge Biologics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.